PMID- 31277114
OWN - NLM
STAT- MEDLINE
DCOM- 20190715
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 27
DP  - 2019 Jul
TI  - Comparison of the effect of recombinant human pro-urokinase and tirofiban on 
      myocardial blood flow perfusion in ST elevation myocardial infarction patients 
      receiving primary percutaneous coronary intervention: A one-center retrospective 
      observational study.
PG  - e16143
LID - 10.1097/MD.0000000000016143 [doi]
LID - e16143
AB  - Ischemia/reperfusion (I/R) injury is associated with primary percutaneous 
      coronary intervention (PPCI). The current study was performed to compare the 
      effect of tirofiban and recombinant human pro-urokinase (rh-proUK) on the 
      improvement of coronary slow blood after PPCI.Sixty-five ST elevation myocardial 
      infarction (STEMI) patients treated with rh-proUK and an equal number treated 
      with tirofiban after PPCI were employed in the current study. The 
      clinicopathological information regarding the biochemical parameters, 
      thrombolysis in myocardial infarction (TIMI) grade, hemodynamics parameters, 
      thrombus core (TS), sum-STR, left ventricular ejection fraction (LVEF), blood 
      routine parameters, high-sensitivity C-reactive protein (CRP) level, uric acid, 
      hepatorenal function, electrocardiogram (ECG), and echocardiography before and 
      after the interventions were collected. The differences in those parameters 
      between the 2 groups then compared with assess the treatment effect and side 
      effects associated with the both therapies.The results showed that the TIMI level 
      post-intervention (P = .03), the proportion of TIMI myocardial perfusion grade 
      level III (P = .04), the changes in thrombus score (P < .001) in rh-proUK group 
      were significantly higher than those in tirofiban group while the corrected TIMI 
      Frame Count (CTFC) (P = .02), the incidence of slow flow (P = .02), the thrombus 
      score post-intervention (P < .001), the stent length (P = .02), and the number of 
      receiving administration of sodium nitroprusside (P = .01) were significantly 
      lower than those in tirofiban group. Moreover, the levels of CK (P < .001), CK-MB 
      (P = .01), and NT-proBNP 24-hour post-intervention (P < .02) were significantly 
      lower in rh-proUK group than those in tirofiban group and the sum-STR right after 
      the intervention (P < .03) of rh-proUK group was significantly higher than that 
      of tirofiban group. No significant difference was detected between the 2 
      therapies regarding major adverse cardiac events (MACE).The findings outlined in 
      the current study showed that the improvement effect of rh-proUK on blood flow 
      condition was stronger right after the intervention and the therapy had a similar 
      safety when compared with tirofiban during a 30-day follow-up.
FAU - Yao, Zhuhua
AU  - Yao Z
AD  - Department of Cardiology, Tianjin Union Medical Center, Tianjin, China.
FAU - Li, Wenting
AU  - Li W
FAU - Cheng, Lisong
AU  - Cheng L
FAU - Cao, Mingying
AU  - Cao M
FAU - Pang, Zhihua
AU  - Pang Z
FAU - Li, Yongbin
AU  - Li Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - GGX234SI5H (Tirofiban)
RN  - U5NH2JV64T (saruplase)
SB  - IM
MH  - Aged
MH  - Coronary Circulation/*drug effects
MH  - Female
MH  - Fibrinolytic Agents
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Recombinant Proteins/administration & dosage
MH  - Retrospective Studies
MH  - ST Elevation Myocardial Infarction/*surgery
MH  - Tirofiban/*administration & dosage
MH  - Urokinase-Type Plasminogen Activator/*administration & dosage
MH  - Ventricular Function, Left/*drug effects
PMC - PMC6635167
COIS- The authors disclose no conflict of interest.
EDAT- 2019/07/07 06:00
MHDA- 2019/07/16 06:00
PMCR- 2019/07/05
CRDT- 2019/07/07 06:00
PHST- 2019/07/07 06:00 [entrez]
PHST- 2019/07/07 06:00 [pubmed]
PHST- 2019/07/16 06:00 [medline]
PHST- 2019/07/05 00:00 [pmc-release]
AID - 00005792-201907050-00029 [pii]
AID - MD-D-19-00044 [pii]
AID - 10.1097/MD.0000000000016143 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jul;98(27):e16143. doi: 10.1097/MD.0000000000016143.